Sorafenib as treatment for relapsed or refractory pediatric acute myelogenous leukemia

The prognosis for children with acute myelogenous leukemia (AML) has improved with overall survival rates of up to 65% [Pui et al. J Clin Oncol 2011; 29: 551–565]. However, the cure rate for AML lags behind that of acute lymphoblastic leukemia. Advances in AML leukemogenesis are leading to refined r...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric blood & cancer 2012-10, Vol.59 (4), p.756-757
Main Authors: Watt, Tanya C., Cooper, Todd
Format: Article
Language:English
Subjects:
Adolescent
AML
Antineoplastic Agents - therapeutic use
Benzenesulfonates - therapeutic use
Child
Female
Humans
Leukemia, Myeloid, Acute - drug therapy
Male
Niacinamide - analogs & derivatives
pediatrics
Phenylurea Compounds
Protein Kinase Inhibitors - therapeutic use
Pyridines - therapeutic use
Recurrence
relapse
Remission Induction
sorafenib
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The prognosis for children with acute myelogenous leukemia (AML) has improved with overall survival rates of up to 65% [Pui et al. J Clin Oncol 2011; 29: 551–565]. However, the cure rate for AML lags behind that of acute lymphoblastic leukemia. Advances in AML leukemogenesis are leading to refined risk stratification. FMS like tyrosine kinase 3 (FLT3) mutations are independently associated with a poor prognosis. Newer kinase inhibitors, including sorafenib, have shown promise in adult studies. We report three pediatric patients with relapsed AML who achieved a sustained remission with sorafenib. Further trials are necessary to understand the role of sorafenib in pediatric AML. Pediatr Blood Cancer 2012;59:756–757. © 2011 Wiley Periodicals, Inc.
ISSN:1545-5009
1545-5017
DOI:10.1002/pbc.23394